Botanix Pharmaceuticals (CRYPTO: BOT) — Company Overview, News & Financial Data
Botanix Pharmaceuticals is a dermatology company developing topical treatments for serious skin conditions like axillary hyperhidrosis.
Botanix Pharmaceuticals
Botanix Pharmaceuticals is a clinical and commercial stage dermatology company focused on the development and commercialisation of novel topical treatments for common skin diseases and bacterial infections. Headquartered in Australia with operations in the United States, the company's lead commercial product is Sofdra (sofpironium) topical gel, an FDA-approved prescription gel indicated for the treatment of primary axillary hyperhidrosis. Botanix also advances a novel pipeline of topical antimicrobial and anti-inflammatory candidates utilizing drug delivery technologies to treat dermatological conditions such as acne, papulopustular rosacea, and superficial skin infections caused by resistant bacteria.
Snapshot
Operations
Products and/or services of Botanix Pharmaceuticals
- Primary Hyperhidrosis Treatment: An FDA-approved topical anticholinergic prescription gel formulated with sofpironium bromide at a twelve point forty-five percent concentration for the commercial treatment of primary axillary hyperhidrosis in adult and pediatric patients.
- Acne Vulgaris Pipeline Candidate: A clinical-stage topical formulation candidate developed for the treatment of moderate to severe acne vulgaris through targeted reduction of sebum production, localized inflammation, and follicular hyperkeratinization in patient dermatological trials.
- Antimicrobial Decolonization Candidate: A novel topical antimicrobial drug candidate targeting Staphylococcus aureus infections, developed for nasal decolonization to prevent surgical site complications and manage recurrent superficial bacterial skin infections in clinical settings.
- Papulopustular Rosacea Candidate: A phase two clinical-stage topical formulation designed to target specific inflammatory pathways for the treatment of moderate to severe papulopustular rosacea and associated facial skin erythema and inflammatory lesions.
- Topical Drug Delivery Technology: A proprietary topical delivery formulation platform engineered to enhance skin penetration, improve active drug bioavailability, and enable controlled localized delivery of pharmaceutical compounds through dermal barriers for various dermatological indications.
- Commercial Distribution Infrastructure: United States commercial distribution and medical affairs operations supporting prescription sales, product logistics, specialty pharmacy distribution networks, physician education, and patient access support programs for prescription dermatological therapies.
Botanix Pharmaceuticals executive team
- Mr. Vincent P. IppolitoMD & Executive Chairman
- Dr. Howie McKibbonChief Executive Officer
- Mr. Graeme MorisseyChief Financial Officer
- Mr. Chris LesovitzChief Financial Officer of United States of America
- Dr. Boris Meyerson Ph.D.Chief Business Officer
- Mr. David MorganHead of Corporate Affairs
- Mr. Kevin WojciechowskiHead of HCP Marketing & Sales Training
- Mr. Andrew BickleyJoint Company Secretary
- Mr. Darin Van ArsdaleDirector of Sales Operations